Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Thalidomide and dexamethasone: therapy for multiple myeloma.

Shaji Kumar1, S Vincent Rajkumar

  • 1Division of Hematology, Department of Internal Medicine, Mayo Clinic and Foundation, Rochester, MN 55905, USA. kumar.shaji@mayo.edu

Expert Review of Anticancer Therapy
|October 14, 2005
PubMed
Summary

Thalidomide combined with dexamethasone shows significant efficacy in treating multiple myeloma, achieving about 70% response rates in newly diagnosed patients. This combination therapy offers a valuable option for multiple myeloma management.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

BiTEing the Tumor.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2020
Same author

Increased Bone Marrow Plasma-Cell Percentage Predicts Outcomes in Newly Diagnosed Multiple Myeloma Patients.

Clinical lymphoma, myeloma & leukemia·2020
Same author

Deepening responses associated with improved progression-free survival with ixazomib versus placebo as posttransplant maintenance in multiple myeloma.

Leukemia·2020
Same author

Medication Shortages During the COVID-19 Crisis: What We Must Do.

Mayo Clinic proceedings·2020
Same author

A validated composite organ and hematologic response model for early assessment of treatment outcomes in light chain amyloidosis.

Blood cancer journal·2020
Same author

Multiple myeloma: 2020 update on diagnosis, risk-stratification and management.

American journal of hematology·2020

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Background:

  • Multiple myeloma is an incurable plasma cell malignancy.
  • Current treatments like high-dose therapy and stem cell transplantation have limitations.
  • Thalidomide has emerged as a significant therapeutic advance for multiple myeloma.

Purpose of the Study:

  • To evaluate the efficacy and role of thalidomide in multiple myeloma treatment.
  • To assess the combination therapy of thalidomide and dexamethasone.
  • To understand the mechanisms of action of thalidomide in multiple myeloma.

Main Methods:

  • Clinical evaluation of thalidomide and dexamethasone combination therapy.
  • Analysis of treatment response rates in newly diagnosed and relapsed multiple myeloma.

Related Experiment Videos

  • Assessment of thalidomide's mechanisms including antiangiogenesis, immunomodulation, and apoptosis induction.

    • Main Results:

    • The combination of thalidomide and dexamethasone demonstrated remarkable activity, with overall response rates of approximately 70% in newly diagnosed multiple myeloma.
    • This combination is effective in both newly diagnosed and relapsed disease phases.
    • Synergistic effects observed between thalidomide and corticosteroids.

    Conclusions:

    • The combination of thalidomide and dexamethasone is an important addition to multiple myeloma therapy.
    • It is utilized as induction therapy prior to stem cell transplant and for patients with inadequate response to dexamethasone alone.
    • Ongoing research is exploring thalidomide analogs with improved safety profiles.